{
  "source": "PA-Med-Nec-Orencia.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2201-13\nProgram Prior Authorization/Medical Necessity\nMedication *Orencia® (abatacept)\n*This program applies to the subcutaneous formulation of abatacept\nP&T Approval Date 5/2020, 11/2020, 6/2021, 12/2021, 3/2022, 11/2022, 1/2023, 4/2023,\n7/2023, 1/2024, 2/2024, 10/2024, 4/2025\nEffective Date 6/1/2025\n1. Background:\nOrencia® (abatacept) is a selective T-cell costimulation modulator indicated for the treatment\nof adult patients with moderately to severely active rheumatoid arthritis, patients 2 years of\nage and older with moderately to severely active polyarticular juvenile idiopathic arthritis,\nand patients 2 years of age and older with active psoriatic arthritis.\nConcomitant used of Orencia with other immunosuppressives (e.g., biologic disease-\nmodifying antirheumatic drugs, Janus kinase (JAK) inhibitors) is not recommended.\n2. Coverage Criteriaa:\nA. Rheumatoid Arthritis (RA)\n1. Initial Authorization\na. Orencia will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active rheumatoid arthritis\n-AND-\n(2) One of the following:\n(a) Both of the following:\ni. One of the following:\na. History of failure to a 3 month trial of one non-biologic disease\nmodifying anti-rheumatic drug (DMARD) [e.g., methotrexate,\nleflunomide, sulfasalazine, hydroxychloroquine] at maximally\nindicated doses, unless contraindicated or clinically significant\nadverse effects are experienced (document drug, date, and duration of\ntrial)b\n-OR-\nb. Patient has been previously treated with a targeted immunomodulator\nFDA-approved for the treatment of rheumatoid arthritis as\n© 2025 UnitedHealthcare Services, Inc.\n1\ndocumented by claims history or submission of medical records\n(Document drug, date, and duration of therapy) [e.g., Cimzia\n(certolizumab), adalimumab, Simponi (golimumab), Olumiant\n(baricitinib), Rinvoq (upadacitinib), Xeljanz/Xeljanz XR (tofacitinib),\nEnbrel (etanercept)]\n-AND-\nii",
    ", and duration of therapy) [e.g., Cimzia\n(certolizumab), adalimumab, Simponi (golimumab), Olumiant\n(baricitinib), Rinvoq (upadacitinib), Xeljanz/Xeljanz XR (tofacitinib),\nEnbrel (etanercept)]\n-AND-\nii. History of failure, contraindication, or intolerance to two of the following\npreferred products (Document drug, date, and duration of trial):\na. One of the preferred adalimumab productsc\nb. Cimzia (certolizumab)\nc. Enbrel (etanercept)\nd. Rinvoq (upadacitinib)\ne. Simponi (golimumab)\nf. Xeljanz/Xeljanz XR (tofacitinib)\n-OR-\n(b) Both of the following:\ni. Patient is currently on Orencia therapy as documented by claims history\nor submission of medical records (Document date and duration of\ntherapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in\nthe prescriber’s office, or any form of assistance from the Bristol-\nMyers Squibb sponsored Orencia® Co-Pay Program™ (e.g., sample\ncard which can be redeemed at a pharmacy for a free supply of\nmedication) as a means to establish as a current user of Orencia*\n-AND-\n(3) Patient is not receiving Orencia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib)]\n-AND-\n(4) Prescribed by or in consultation with a rheumatologist\n* Patients requesting initial authorization who were established on therapy via the receipt\nof a manufacturer supplied sample at no cost in the prescriber’s office or any form of\nassistance from the Bristol-Myers Squibb sponsored Orencia® Co-Pay Program™ shall\nbe required to meet initial authorization criteria as if patient were new to therapy.\n© 2025 UnitedHealthcare Services, Inc.\n2\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Orencia will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Orencia therapy\n-AND-\n(2) Patient is not receiving Orencia in combination ",
    "zation\na. Orencia will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Orencia therapy\n-AND-\n(2) Patient is not receiving Orencia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib)]\nAuthorization will be issued for 12 months.\nB. Juvenile Idiopathic Arthritis (JIA)\n1. Initial Authorization\na. Orencia will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active polyarticular juvenile idiopathic\narthritis.\n-AND-\n(2) Patient is not receiving Orencia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib)]\n-AND-\n(3) Prescribed by or in consultation with a rheumatologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Orencia will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Orencia therapy\n-AND-\n(2) Patient is not receiving Orencia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n© 2025 UnitedHealthcare Services, Inc.\n3\n(golimumab), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib)]\nAuthorization will be issued for 12 months.\nC. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Orencia will be approved based on all of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) One of the following:\n(a) Both of the following:\ni. One of the following:\na. History of failure to a 3 month trial of methotrexate at maximally\nindicated dose, unless contraindicated or clinically significant adverse\neffects are experienced (document date and duration of trial)b\n-OR-\nb. Patient has been previously ",
    "f methotrexate at maximally\nindicated dose, unless contraindicated or clinically significant adverse\neffects are experienced (document date and duration of trial)b\n-OR-\nb. Patient has been previously treated with a targeted immunomodulator\nFDA-approved for the treatment of psoriatic arthritis as documented\nby claims history or submission of medical records (Document drug,\ndate, and duration of therapy) [e.g., Cimzia (certolizumab),\nadalimumab, Simponi (golimumab), ustekinumab, Tremfya\n(guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast),\nSkyrizi (risankizumab), Enbrel (etanercept)]\n-AND-\nii. One of the following:\na. History of failure, contraindication, or intolerance to two of the\nfollowing preferred products: (document drug, date, and duration of\ntrial)\n1. One of the preferred adalimumab productsc\n2. Cimzia (certolizumab)\n3. Cosentyx (secukinumab)\n4. Enbrel (etanercept)\n5. Rinvoq (upadacitinib)\n6. Simponi (golimumab)\n7. Skyrizi (risankizumab-rzaa)\n© 2025 UnitedHealthcare Services, Inc.\n4\n8. One of the preferred ustekinumab productsc\n9. Tremfya (guselkumab)\n10. Xeljanz/Xeljanz XR (tofacitinib)\n-OR-\nb. Both of the following:\n1. Patient is less than 18 years of age\n-AND-\n2. History of failure, contraindication, or intolerance to one of the\npreferred ustekinumab productsc ustekinumab or Enbrel\n(etanercept) (document date and duration of trial)\n-OR-\n(b) Both of the following:\ni. Patient is currently on Orencia therapy as documented by claims history\nor submission of medical records (Document date and duration of\ntherapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in\nthe prescriber’s office, or any form of assistance from the Bristol-\nMyers Squibb sponsored Orencia® Co-Pay Program™ (e.g., sample\ncard which can be redeemed at a pharmacy for a free supply of\nmedication) as a means to establish as a current user of Orencia*\n-AND-\n(3) Patient is not receiving Orencia in combination with another targeted\nimmunomodulator [e.g.",
    " a pharmacy for a free supply of\nmedication) as a means to establish as a current user of Orencia*\n-AND-\n(3) Patient is not receiving Orencia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya\n(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\n-AND-\n(4) Prescribed by or in consultation with one of the following:\n(a) Rheumatologist\n(b) Dermatologist\n* Patients requesting initial authorization who were established on therapy via the receipt\nof a manufacturer supplied sample at no cost in the prescriber’s office or any form of\n© 2025 UnitedHealthcare Services, Inc.\n5\nassistance from the Bristol-Myers Squibb sponsored Orencia® Co-Pay Program™ shall\nbe required to meet initial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Orencia will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Orencia therapy\n-AND-\n(2) Patient is not receiving Orencia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya\n(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.\nc For a list of preferred products please reference drug coverage tools.\n3. Additional Clinical Rules:\n• Supply limits",
    "necticut, Kentucky and Mississippi business only a 30-day trial will be required.\nc For a list of preferred products please reference drug coverage tools.\n3. Additional Clinical Rules:\n• Supply limits may be in place.\nThe intravenous infusion is typically covered under the medical benefit. Please refer to the United\nHealthcare Medical Benefit Drug Policy for Orencia.\n4. References:\n1. Orencia [package insert]. Princeton, NJ: Bristol-Myers Squibb; October 2023.\n2. Pavy S. Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: clinical\npractice guidelines based on published evidence and expert opinions. Joint Bone Spine\n2006;73(4):388-95.\n3. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for\nthe Treatment of Rheumatoid Arthritis. Arthritis Care & Research. Arthritis Rheum.\n2016;68(1):1-26.\n4. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and\nPsoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol.\n2016 May;68(5):1060-71.\n5. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of\npsoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-50.\n© 2025 UnitedHealthcare Services, Inc.\n6\n6. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for treatment with an\nemphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.\n7. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis\nwith topical therapies. J Am Acad Dermatol 2009;60(4):643-59.\n8. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic",
    "ment and treatment of psoriasis\nwith topical therapies. J Am Acad Dermatol 2009;60(4):643-59.\n8. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Guidelines of care for the treatment of psoriasis with phototherapy and\nphotochemotherapy. J Am Acad Dermatol 2010;62(1):114-35.\n9. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Guidelines of care for the management and treatment of psoriasis with\ntraditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.\n10. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care for\nthe management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment\nof psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J\nAm Acad Dermatol. 2011 Jul;65(1):137-74.\n11. Gossec L, et al; European League Against Rheumatism (EULAR) recommendations for the\nmanagement of psoriatic arthritis with pharmacological therapies: 2015 update, Ann Rheum Dis\n2016;75:499-510.\nProgram Prior Authorization/Medical Necessity - Orencia (abatacept)\nChange Control\n5/2020 New program\n11/2020 Added Tremfya as a step therapy medication for psoriatic arthritis.\nUpdated background and references.\n6/2021 Removed prescriber requirement from reauthorization criteria. Added\ncoverage criteria for patients previously treated with a biologic\nDMARD. Added clarification that submission of medical records is\nrequired documenting current therapy with Orencia in order to bypass\nstep if claim history not available.\n12/2021 Updated conventional DMARD bypass language for rheumatoid\narthritis and psoriatic arthritis with no change to clinical intent. Updated\nCT/KY footnote.\n3/2022 Added Skyrizi as a preferred drug for active psoriatic arthritis.\n11/2022 Added Enbrel as a preferred step product for RA. Added Enbrel,\nRinvoq, and Xeljanz as preferred step products",
    "footnote.\n3/2022 Added Skyrizi as a preferred drug for active psoriatic arthritis.\n11/2022 Added Enbrel as a preferred step product for RA. Added Enbrel,\nRinvoq, and Xeljanz as preferred step products for PsA. Added Enbrel\nand Rinvoq as an example where appropriate. Added Mississippi to\nstate mandate footnote.\n1/2023 Updated step therapy requirements to Humira or Amjevita. Updated\nlisted examples from Humira to adalimumab.\n4/2023 Updated step therapy requirement from Humira or Amjevita to one of\nthe preferred adalimumab products and added the footnote “For a list of\npreferred adalimumab products please reference drug coverage tools.”\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n1/2024 Updated PsA criteria based on updated indication for patients 2 years of\nage or older. Updated Background, References, and state mandate\nfootnote.\n© 2025 UnitedHealthcare Services, Inc.\n7\n2/2024 Removed Olumiant as a preferred product for RA.\n10/2024 Updated RA and PsA step requirement noting Adalimumab-adaz\n(unbranded Hyrimoz), Amjevita for Nuvaila, and Humira as preferred\nadalimumab products with no change to clinical intent. Added\nCosentyx as a step therapy drug for PsA. Removed preferred\nadalimumab footnote.\n4/2025 Removed examples for adalimumab in step therapy. Changed Stelara\nstep therapy to “One of the preferred ustekinumab productsc”. Changed\nStelara example to Ustekinumab. Added the footnote “For a list of\npreferred products please reference drug coverage tools.”\n© 2025 UnitedHealthcare Services, Inc.\n8"
  ]
}